Buspirone in Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 3, Issue 1, 2003, Pages 19-28

  Desai, Abhilash K ^a   Grossberg, George T ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Anxiety; Buspirone; Generalized anxiety disorder

Indexed keywords

BUSPIRONE;

AGITATION; ALZHEIMER DISEASE; ANXIETY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INSTITUTIONALIZATION; NERVE DEGENERATION; NEUROTRANSMITTER RELEASE; REVIEW; RISK BENEFIT ANALYSIS; SEROTONINERGIC NERVE CELL;

EID: 0037226930     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.1.19     Document Type: Review

References (88)

1. Cummings JL, Cole G. Alzheimer's disease. JAMA 287, 2335-2338 (2002).
2. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88, 1337-1342 (1998).
3. Desai AK, Grossberg GT. Recognition and management of behavioral disturbances in dementia. Primary Care Companion. J. Clin. Psychiatry 3, 93-109 (2001).
4. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am. J. Psychiatry 147, 1049-1051 (1990).
5. Balestreri L, Grossberg GT. BPSD as a risk factor for nursing home placement. Poster presented at the Annual Symposium of the American Medical Directors Association. San Francisco, CA, USA, March 16-19, 2000.
6. Ballard C, Boyle A, Bowler C, Lindesay J. Anxiety disorders in dementia sufferers. Int J. Geriatr. Psychiatry 11, 987-990 (1996).
7. Jost B, Grossberg G. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J. Am. Geriatr. Soc. 44, 1078-1081 (1996).
8. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 46, 130-135 (1996).
9. Ownby RL, Harwood DG, Barker WW, Duara R. Predictors of anxiety in patients with Alzheimer's disease. Depress. Anxiety 11, 38-42 (2000).
10. Reisberg B, Borenstein J, Salob SP et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J. Clin. Psychiatry 48, 9-15 (1987).
11. Ferretti L, McCurry SM, Logsdon R, Gibbons L, Teri L. Anxiety and Alzheimer's disease. J. Geriatr. Psychiatry Neurol. 14, 52-58 (2001).
12. Ballard CG, Mohan-Ramalingam NC, Patel A, Graham C. Anxiety disorders in dementia. Br. J. Psychol. Med. 11, 108-109 (1994).
13. Bungener C, Jouvent R, Derousesne C. Affective disturbances in Alzheimer's disease. J. Am. Geriatr. Soc. 44, 1066-1071 (1996).
14. Chemerinski E, Petracca G, Manes F et al. Prevalence and correlates of anxiety in Alzheimer's disease. Depress. Anxiety 7, 166-170 (1998).
15. Brown TA. The nature of generalized anxiety disorder and pathological worry: current evidence and conceptual models. Can. J. Psychiatry 42, 817-825 (1997).
16. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. Parts I-IV. Br. J. Psychiatry (1990).
17. Aarsland D, Cummings JL, Yenner G, Miller B. Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. Am. J. Psychiatry 153, 243-247 (1996).
18. Swearer JM, Drachman DA, O'Donnell BF, Mitchell AL. Troublesome and disruptive behaviors in dementia: relationships to diagnosis and disease severity. J. Am. Geriatr. Soc. 36, 784-790 (1988).
19. Tiberti C, Sabe L, Kuzis G et al. Prevalence and correlates of the catastrophic reactions in Alzheimer's disease. Neurology 50, 546-548 (1998).
20. Weiner MF, Svedik D, Risser RC. What depressive symptoms are reported in Alzheimer's patients? Int. J. Geriatr. Psychiatry 12, 648-452 (1997).
21. Teri L, Ferretti LE, Gibbons LE et al. Behavioral symptoms in Alzheimer's disease: prevalence and comorbidity. J. Gerontol. Med. Sci. 54A, M348-M352 (1999).
22. Mintzer JE, Brawman-Mintzer O. Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. J. Clin. Psychiatry 57(Suppl. 7), 55-63 (1996).
23. Schneider LS. Overview of generalized anxiety disorder in the elderly. J. Clin. Psychiatry 57(Suppl. 7), 34-45 (1996).
24. Finlayson RE, Davis LJ. Prescription drug dependence in the elderly population: Demographic and clinical features of 100 in-patients. Mayo Clin. Proc. 69, 1137-1145 (1994).
25. Katz J, Winger G. Benzodiazepines: use, abuse and consequences. Pharmacol. Rev. 44, 151-347 (1992).
26. Llorente MD, David D, Golden AG et al. Defining patterns of benzodiazepine use in older adults. J. Geriatr. Psychiatry Neurol. 13(3), 150-160 (2000).
27. Szwabo PA. Substance abuse in older women. Curr. Geriatr Med. 9, 197-208 (1993).
28. Fourrier A, Letenneur L, Dartigues JF, Moore N, Begaud B. Benzodiazepine use in an elderly community-dwelling population. Characteristics of users and factors associated with subsequent use. Eur. J. Clin. Pharmacol. 57(5), 419-425 (2001).
29. Kirby M, Denihan A, Bruce I, Radic A, Coakley D, Lawlor BA. Benzodiazepine use among the elderly in the community. Int. J. Geriatr. Psychiatry 14(4), 280-284 (1999).
30. Miller NS, Belkin BM, Gold MS. Alcohol and drug dependence among the elderly: epidemiology, diagnosis and treatment. Compr. Psychiatry 32(2), 153-165 (1991).
31. Buck JA. Psychotropic drug practice in nursing homes. J. Am. Geriatr. Soc. 36, 409-418 (1988).
32. Gill SS, Misiaszek BC, Brymer C. Improving prescribing in the elderly: a study in the long-term care setting. Can. J. Clin. Pharmacol. 8(2), 78-83 (2001).
33. Stem RG, Duffelmeyer ME, Zemishlani Z et al. The use of benzodiazepines in the management of behavioral symptoms in dementia patients. Psychiatr. Clin. N. Am. 14, 375-384 (1991).
34. Kirven LE, Montero EF. Comparison of thioridazine and diazepam in the control of nonpsychotic symptoms associated with senility: double-blind study. J. Am. Geriatr. Soc. 21, 546-551 (1973).
35. Coccaro EF, Kramer E, Zemishlany Z et al. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am. J. Psychiatry 147, 1640-1656 (1990).
36. Covington J. Alleviating agitation, apprehension and related symptoms in geriatric patients. South Med. J. 68, 719-724 (1975).
37. Stotsky B. Multicenter study comparing thioridazine and diazepam and placebo in elderly nonpsychotic patients with emotional and behavioral disorders. Clin. Ther. 6, 546-559 (1984).
38. Cevera AA. Psychoactive drug therapy in the senile patient: controlled comparison of thioridazine and diazepam. Psychiatry Digest 15-21 (1974).
39. Beber CR. Management of behavior in the institutionalized aged. Dis. Nerv. Syst. 26, 591-595 (1965).
40. Lemos GP, Clement MA, Nickels E. Effects of diazepam suspension in geriatric patients hospitalized for psychiatric illnesses. J. Am. Geriatr. Soc. 13, 355-359 (1965).
41. Rabins P, Blacker D, Bland W et al. Treatment of patients with Alzheimer's disease and other dementias of late-life. In: Practice Guidelines for the treatment of psychiatric disorders. American Psychiatric Association, Washington DC, USA, 69-137 (2002).
42. Starr JM, Whalley LJ. Drug-induced dementia. Incidence, management and prevention. Drug Safety 11(5), 10-17 (1994).
43. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 15(1), 15-28 (1999).
44. Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Safety 21(2), 101-122 (1999).
45. Salzman C, Fisher J, Nobel K et al. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. Int. J. Geriatric Psychiatry 7, 89-93 (1992).
46. Lechin F, van der Dijs B, Benaim M. Benzodiazepines: tolerability in elderly patients. Psychother. Psychosom. 65(4), 171-182 (1996).
47. Schneider LS. Efficacy of treatment for geropsychiatric patients with severe mental illness. Psychopharmacol. Bull. 29(4), 501-524 (1993).
48. Palmer AM, Stratman GC, Procter AW et al. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann. Neurol. 23, 616-620 (1988).
49. Lanctot KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J. Neuropsychiatry Clin. Neurosci. 13(1), 5-21 (2001).
50. Siever LJ, Kahn RS, Lawlor BA et al. Critical issues in defining the role of serotonin in psychiatric disorders. Pharmacol. Rev. 43, 509-525 (1991).
51. Dubovksy SL, Thomas M. Serotonergic mechanisms and current and future psychiatric practice. J. Clin. Psychiatry 56(Suppl. 2), 38-48 (1995).
52. Fuller RW. Role of serotonin in therapy of depression and related disorders. J. Clin. Psychiatry 52(Suppl. 5), 52-57 (1991).
53. Apter JT, Allen LA. Buspirone: future directions. J. Clin. Psychopharmacol. 19(1), 86-93 (1999).
54. Krasucki C, Howard R, Mann A. Anxiety and its treatment in the elderly. Int. Psychogeriatrics 11, 25-45 (1999).
55. Ninan PT, Cole JO, Yonkers KA. Nonbenzodiazepine Anxiolytics. In: Textbook of Psychopharmacology 2nd edition. Shatzberg AF, Nemeroff CB (Eds). American Psychiatric Press Inc., Washington DC, USA, 287-300 (1998).
56. Hyler SE. Psychotropic drug interactions. Primary Psychiatry 9(3), 27-57 (2002).
57. Barbee JG, McLaulin JB. Anxiety disorders: Diagnosis and pharmacotherapy in the elderly. Psychiatric Annals 20, 439-445 (1990).
58. Gammans RE, Westrick ML, Shea JP et al. Pharmacokinetics of buspirone in elderly subjects. J. Clin. Pharmacol. 29, 72-78 (1989).
59. Napoliello MJ. An interim multicentre report on 677 anxious geriatric out-patients treated with buspirone. Br. J. Clin. Pract. 40, 71-73 (1986).
60. Bohm C, Robinson DS, Gammans RE et al. Buspirone therapy in anxious elderly patients: a controlled clinical trial. J. Clin. Psychopharmacol. 10(Suppl. 3), 47S-51S (1990).
61. Dada F, Sethi S, Grossberg GF. Generalized anxiety disorder in the elderly. Psychiatric Clin. N. Am. 24(1), 155-164 (2001).
62. Robinson DS, Napoliello MJ, Schenk J. The safety and usefulness of buspirone as an anxiolytic drug in elderly versus young patients. Clin. Ther. 10, 740-746 (1988).
63. Schweizer E. Generalized anxiety disorder: longitudinal course and pharmacologic treatment. Psychiatr. Clin. N. Am. 18, 843-857 (1995).
64. Young RC, Meyers BS. Psychopharmacology. In: Comprehensive Review of Geriatric Psychiatry-II. Sadavoy J, Lazarus LW, Jarvik LF, Grossberg GT (Eds). American Psychiatric Press Inc., Washington DC, USA, 755-817 (1996).
65. Cantillon M, Brunswick R, Molina D et al. Buspirone vs. haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease. Am. J. Geriatr. Psychiatry 4, 263-267 (1996).
66. Levy MA. A trial of buspirone for the control of disruptive behaviors in community-dwelling patients with dementia. Int. J. Geriatric Psychiatry 9, 841-848 (1994).
67. Sakauye KM, Camp CJ, Ford PA. Effects of buspirone on agitation associated with dementia. Am. J. Geriatr. Psych. 1, 82-84 (1993).
68. Herrmann N, Eryavec G. Buspirone in the management of agitation and aggression associated with dementia. Am. J. Geriatr. Psych. 1, 249-253 (1993).
69. Colenda C. Buspirone in treatment of agitated demented patients. Lancet 21, 1169 (1988).
70. Tiller JWG, Dakis JA, Shaw JM. Short-term buspirone treatment in disinhibition with dementia. Lancet 2(8609), 510 (1988).
71. Cooper JW, Cobb HH III, Burfield AH. Effects of psychotropic load reduction and buspirone conversion on behavioral disturbances in a nursing home population. Consult Pharm. 16, 358-363 (2001).
72. Cooper J. Consultant pharmacist assessment and reduction of fall risk in nursing facilities. Consult Pharmacist 12, 1294-1304 (1997).
73. Cooper J. Consultant pharmacist assessment of psychoactive fall injury incidence and costs within the nursing facility. Consult Pharm. 12, 1305-1309 (1997).
74. Lawlor BA, Radcliffe J, Molchan SE et al. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer's disease. Int. J. Geriatr. Psychiatry 9, 55-59 (1994).
75. Stanislav SW, Fabre T, Crismon ML, Childs A. Buspirone's efficacy in organic-induced aggression. J. Clin. Psychopharmacol. 14(2), 126-130 (1994).
76. Batki SL. Buspirone in drug users with AIDS or AIDS-related complex. J. Clin. Psychopharmacol. 10(Suppl. 3), S111-S115 (1990).
77. Ratey J, Sovner R, Parks A et al. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple baseline, placebo lead-in-study. J. Clin. Psychiatry 52, 159-162 (1991).
78. Guay DRP, Lott A. Agitation/aggression in patients with dementia and developmental disability. Consult Pharm. 11, 149-165 (1996).
79. Herrmann N. Use of SSRIs in the elderly: obvious benefits but unappreciated risks. Can. J. Clin. Pharmacol. 7(2), 91-95 (2000).
80. Cooper JW. Falls and fractures in nursing home patients receiving psychotropic drugs. Int. J. Geriatric Psychiatry 9, 975-980 (1994).
81. Street J, Clark WS, Gannon KS et al. Olanzapine treatment of psychosis and behavioral disturbances in patients with Alzheimer's disease in nursing care facilities. Arch. Gen. Psychiatry 57, 968-976 (2000).
82. Markovitz PJ. Treatment of anxiety in the elderly. J. Clin. Psychiatry 54, (1993).
83. Sheikh JI, Salzman C. Anxiety in the elderly. Course and treatment. Psychiatr. Clin. N. Am. 18(4), 871-883 (1995).
84. Rovner BW, German PS, Bwadhead J et al. The prevalence and management of dementia and other psychiatric disorders in nursing homes. Int. Psychogeriatr. 2, 13-24 (1990).
85. Mathews FE, Dening T. Prevalence of dementia in institutional care. Lancet 360, 225-226 (2002).
86. Avorn J, Gurwitz JH. Drug use in the nursing home. Arch. Int. Med. 123, 195-204 (1995).
87. Rakel RE. Long-term buspirone therapy for chronic anxiety: A multicenter international study to determine safety. South Med J. 15, 186-192 (1990).
88. Lyketsos C, Olin J. Depression in Alzheimer's disease: overview and treatment. Biol. Psychiatry 52(3), 243 (2002).